The world's largest event on psychedelics will feature over 600 speakers and is expected to attract thousands of participants in June 2025 in the United States.

Study from Imperial College London reveals that the use of psychedelics during the COVID-19 pandemic was associated with improvement in symptoms of anxiety and depression, even outside of controlled therapeutic contexts

Article addressing the use of psychedelics in the treatment of the disease available in full in the 3rd Sechat Cannabis Guide.

Podcast explores psychedelia, mental health, philosophy, and humor

A new study from the University of Basel rescues an old question with the delicacy of offering shelter: what if the cure lies in the courage to dive deep?

Ketamine as an ally in the treatment of resistant depression and suicidal thoughts

The mixture released in the 90s may have analgesic potential

Understanding the Risks and Effects of Excessive Consumption

Studies, reports, and therapeutic experiences point to the use of substances such as MDMA, psilocybin, ketamine, and cannabis in caring for individuals with PTSD after sexual violence

The debate brought together experts in law, science, and ethics to discuss evidence, risks, and regulatory models for the therapeutic use of these substances

The DEA has increased the legal quotas for the production of psychedelics such as psilocybin and DMT for 2026, focusing on scientific and medical research in the United States.

Specialist details how MDMA acts in the brain and the promising results in patients resistant to conventional therapies